Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

(2019) Yuankai Shi et al.   Lancet Haematology

Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases

(2019) Rossella Talotta et al.   Immunotherapy

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

(2018) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials

(2018) C. Bryce Johnson et al.   OncoImmunology

Changing the Natural History of Non–Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade

(2017) Daniel S.W. Tan   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

(2017) Robert Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors

(2016) Shruti Agrawal et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

(2015) B Homet Moreno et al.   BRITISH JOURNAL OF CANCER

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Practical Considerations for the Pharmacokinetic and Immunogenic Assessment of Antibody–Drug Conjugates

(2014) Melody Sauerborn et al.   BIODRUGS

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

(2014) C. Wang et al.   Cancer Immunology Research

Human Hemato-Lymphoid System Mice: Current Use and Future Potential for Medicine

(2013) Anthony Rongvaux et al.   Annual Review of Immunology

Challenges and approaches for the development of safer immunomodulatory biologics

(2013) Jean G. Sathish et al.   NATURE REVIEWS DRUG DISCOVERY

Conservation and divergence in the transcriptional programs of the human and mouse immune systems

(2013) T. Shay et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunogenicity testing strategy and bioanalytical assays for antibody–drug conjugates

(2013) Sarah A Hoofring et al.   Bioanalysis

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

(2008) Gopi Shankar et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS